Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines. - Wikidata - wikimedia - TriplyDB

Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines.

Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines.

http://www.wikidata.org/entity/Q35234194

about

Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients.Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors Metabolically incorporated photocrosslinking sialic acid covalently captures a ganglioside-protein complex.Robust immune responses elicited by a fully synthetic three-component vaccine.Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriers Metabolism of diazirine-modified N-acetylmannosamine analogues to photo-cross-linking sialosides.Carbohydrate engineered cells for regenerative medicine.Total synthesis of trifluorobutyryl-modified, globally protected sialyl Lewis x by a convergent [2+2] approach Modified GM3 gangliosides produced by metabolic oligosaccharide engineering Synthesis and Evaluation of Protein Conjugates of GM3 Derivatives Carrying Modified Sialic Acids as Highly Immunogenic Cancer Vaccine Candidates Identification of sialylated glycoproteins from metabolically oligosaccharide engineered pancreatic cells.Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse A novel cancer immunotherapy based on the combination of a synthetic carbohydrate-pulsed dendritic cell vaccine and glycoengineered cancer cells.Recent Development in Carbohydrate Based Anti-cancer Vaccines.Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cell.A novel synthetic bipartite carrier protein for developing glycotope-based vaccines.A Fully Synthetic Self-Adjuvanting Globo H-Based Vaccine Elicited Strong T Cell-Mediated Antitumor Immunity.Lipid-Mediated Targeting with Membrane-Wrapped Nanoparticles in the Presence of Corona Formation Fully Synthetic Self-Adjuvanting α-2,9-Oligosialic Acid Based Conjugate Vaccines against Group C Meningitis.Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines Synthetic and immunological studies of 5'-N-phenylacetyl sTn to develop carbohydrate-based cancer vaccines and to explore the impacts of linkage between carbohydrate antigens and carrier proteins Parallel chemoenzymatic synthesis of sialosides containing a C5-diversified sialic acid Combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy.Carbohydrate vaccines: developing sweet solutions to sticky situations?Recent development in carbohydrate-based cancer vaccines.Eliciting carbohydrate-specific immune response against sialosides: success and challenges.Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies.Carbohydrate-based cancer vaccines: target cancer with sugar bullets.Discovery and design of carbohydrate-based therapeutics.The sweet side of tumor immunotherapy.Chemoenzymatic Syntheses of Sialylated Oligosaccharides Containing C5-Modified Neuraminic Acids for Dual Inhibition of Hemagglutinins and Neuraminidases.Cloning and characterization of a viral α2-3-sialyltransferase (vST3Gal-I) for the synthesis of sialyl Lewisx.Metabolic glycoengineering bacteria for therapeutic, recombinant protein, and metabolite production applications.Enhanced interferon-gamma secretion and antitumor activity of T-lymphocytes activated by dendritic cells loaded with glycoengineered myeloma antigens.A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.Metabolic Glycoengineering with N-Acyl Side Chain Modified Mannosamines.N-Propionyl polysialic acid precursor enhances the susceptibility of multiple myeloma to antitumor effect of anti-NprPSA monoclonal antibody.Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example.Progress in the synthesis and biological evaluation of lipid A and its derivatives.

P2860

Q21129299-F117A491-8615-4064-8EC7-1918966F390D Q31157425-A904CADE-4C94-423C-99DC-A5BE9F0B61F7 Q33591916-41D6FFDA-B490-4660-A556-B51A3D33DA16 Q33631331-8F067E27-A477-4935-8CEB-B1E2BD931D1D Q33721005-2461B8D1-87DA-46DC-BBB1-7AD726296B41 Q33819711-E378757E-8EB6-4E26-B278-6A88E8B84B93 Q33991792-2212DDFE-7D7B-4952-BCB0-6379CD97836C Q34545778-85EDB635-52D7-4BC7-95D0-8C696689F71E Q34722755-B72D1C40-255F-4523-B3EE-A9CEE860AF4C Q35165149-67D0D324-4DCA-4CAD-B273-04552E34FD15 Q35212122-3AA6C1F2-0D8F-4862-85CD-326B259288E8 Q35615401-95603460-7561-4DE3-A4DE-2D43A9FE6D6F Q35685656-637F6825-AA15-49E8-A9B0-FE687D4F273D Q35741638-481777EB-05F7-4A40-B095-CC3746667CB5 Q35854131-6BDF3CAC-86ED-4D9F-8E47-3442C7539023 Q36166263-86B855BD-F871-46DA-9740-6E07E10F9846 Q36442488-B3AFBFFE-6A42-4790-A076-465189D38076 Q36604334-361FCA8E-1C73-4407-8E89-086CB667972E Q36828184-FA701EA4-5F47-42D5-8D08-33CD92DACEC5 Q36850638-9EA6BE5E-82D5-4B09-BAD7-2719A06DDF99 Q36868822-2A5440AC-68A2-43BF-8889-9DAE6254FC3B Q37120643-D737BA68-7BAB-4D90-93B1-85D9E074C07B Q37366598-A5BAAC13-A908-44EB-940E-4693F0EB246A Q37418500-5CBA09E9-8AFF-409C-A25A-74DA1047E355 Q37426039-AC6ED25C-2F85-4278-9988-C39BC219BBB8 Q37455940-07916A80-CBE5-42D4-9366-69FF046C999F Q37869901-D5DE6595-2AFE-4276-991B-4795B8CAE1AB Q37993590-90670350-0317-4C90-97E7-11748985DCF9 Q38016342-6522C33B-A6D9-4A46-9BD1-FE6EB0822AE1 Q38029137-18419B6B-4F6D-4023-93CA-76D8D66CFE17 Q38031282-A771019B-9157-4D70-B439-1006950AF55D Q38298211-C150B18C-680D-4908-BD41-A5BF0CD82274 Q38339801-79454F53-2607-4E53-ABC9-B37A39B864B3 Q38452524-26001B02-9BF2-463F-97AC-37052C0E5270 Q38548199-953491F7-30A1-491C-88D6-2DCAB81E9EE6 Q38767397-BB18D918-5273-4290-B1AE-74018AFEE628 Q38902441-6DAECCC2-ED03-49DE-A147-A5230586B797 Q39002186-C1DFB72C-142A-4D3E-8726-97885BE5F13C Q39031683-36498C37-B048-436E-922F-505D8A86418D Q39378325-0AE35474-485C-4D9B-AC70-5C92823D4D10

P2860

Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines.

http://www.wikidata.org/entity/Q35234194

description

2005 nî lūn-bûn

@nan

2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Synthesis and immunological pr ...... s therapeutic cancer vaccines.

@ast

Synthesis and immunological pr ...... s therapeutic cancer vaccines.

@en

type

label

Synthesis and immunological pr ...... s therapeutic cancer vaccines.

@ast

Synthesis and immunological pr ...... s therapeutic cancer vaccines.

@en

prefLabel

Synthesis and immunological pr ...... s therapeutic cancer vaccines.

@ast

Synthesis and immunological pr ...... s therapeutic cancer vaccines.

@en

P1433

Q35234194-C3126FE8-5F2A-46A0-8D74-8FB47BA8D4DA

P1476

Q35234194-D951150A-9B9B-4253-8D52-9B6D8209C433

P2093

Q35234194-0E2F8E11-745A-4AB7-A4C7-27291928E504

Q35234194-4A1AA0CE-47D3-4FB5-BBE8-40A7FFB72AE5

Q35234194-5F43A26B-4C28-4027-8B0A-AE500F7DEAC9

Q35234194-75462EEA-7BE7-42C5-B98E-B9265D0309D6

Q35234194-DCC19647-3046-41D2-BB04-41B47B0E4635

P2860

Q35234194-07057EC6-7E57-4E6F-A755-3D02E0C7DE84

Q35234194-13595A5A-15FE-479B-B4BC-D0B55F799644

Q35234194-2198B3C3-9636-493C-8CD8-456036277B58

Q35234194-299CFDBC-3F57-4C3E-B9E1-2DB06F98166E

Q35234194-2A8E6C40-D0B9-47D3-8EED-C5C78DC31FBC

Q35234194-2DBB7FD4-56E3-44E9-A770-BF1F64936E30

Q35234194-3063F146-DF1D-4926-9D4F-78B92DC65B83

Q35234194-3631C219-54E5-4BC0-97C3-F4F2BF5DE4FE

Q35234194-3BF03EF0-9262-4D62-A975-9738207A6D04

Q35234194-48FB4254-1B94-4050-B1AD-D9455EA57CBB

P304

Q35234194-B93709C1-E0F4-4136-911A-0AA534D9D6BF

P31

Q35234194-16B1ADF6-D072-4A92-941A-E112A2287AD3

P356

Q35234194-D87C7A7E-150B-41F8-8052-99BF259C41A8

P407

Q35234194-E2B1BBAC-7D4F-46FD-827D-716256D41DE8

P433

Q35234194-092E5035-0D31-490D-BBDC-69036A6DB71C

P478

Q35234194-C8E051C5-3A7A-4E3D-829E-9B0B46EE3979

P577

Q35234194-A9919EEC-A1B8-4829-BB11-4514253CF2FF

P5875

Q35234194-499ECAB9-DB71-4C3B-8567-78CED4256BD4

P698

Q35234194-F29E1561-3BF7-451C-9ED8-A4C8E2CB5963

P921

Q35234194-D8EFCA19-84CB-4D90-ADB0-BC8C92FEE010

P932

Q35234194-A6AA6C18-D7F0-49CE-82E0-4DCDDC1E41D7

P356

P1433

Journal of Medicinal Chemistry

P1476

Synthesis and immunological pr ...... s therapeutic cancer vaccines.

@en

P2093

Clifford Harding

http://www.w3.org/2001/XMLSchema#string

Nancy Nagy

http://www.w3.org/2001/XMLSchema#string

Peter Chefalo

http://www.w3.org/2001/XMLSchema#string

Yanbin Pan

http://www.w3.org/2001/XMLSchema#string

Zhongwu Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid

Cell surface engineering by a modified Staudinger reaction

Chemical glycobiology

Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

From the Laboratory to the Clinic: A Retrospective on Fully Synthetic Carbohydrate-Based Anticancer Vaccines Frequently used abbreviations are listed in the appendix.

Metabolic delivery of ketone groups to sialic acid residues. Application To cell surface glycoform engineering.

Cancer vaccines: an update with special focus on ganglioside antigens.

Antibody-mediated regulation of cellular immunity and the inflammatory response.

Preparation and immunological studies of protein conjugates of N -acylneuraminic acids.

P304

875-883

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM0494422

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8043718

http://www.w3.org/2001/XMLSchema#string

P698

15689172

http://www.w3.org/2001/XMLSchema#string

P921

P932

3180873

http://www.w3.org/2001/XMLSchema#string